212 related articles for article (PubMed ID: 37069690)
21. Combined inhibition of autophagy and Nrf2 signaling augments bortezomib-induced apoptosis by increasing ROS production and ER stress in pancreatic cancer cells.
Li X; Liang M; Jiang J; He R; Wang M; Guo X; Shen M; Qin R
Int J Biol Sci; 2018; 14(10):1291-1305. PubMed ID: 30123077
[TBL] [Abstract][Full Text] [Related]
22. Loss of tuberous sclerosis complex 2 sensitizes tumors to nelfinavir-bortezomib therapy to intensify endoplasmic reticulum stress-induced cell death.
Johnson CE; Dunlop EA; Seifan S; McCann HD; Hay T; Parfitt GJ; Jones AT; Giles PJ; Shen MH; Sampson JR; Errington RJ; Davies DM; Tee AR
Oncogene; 2018 Nov; 37(45):5913-5925. PubMed ID: 29980790
[TBL] [Abstract][Full Text] [Related]
23. Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.
Pierce MR; Robinson RM; Ibarra-Rivera TR; Pirrung MC; Dolloff NG; Bachmann AS
Leuk Res; 2020 Jan; 88():106271. PubMed ID: 31778912
[TBL] [Abstract][Full Text] [Related]
24. Effects of arsenic trioxide combined with bortezomib on apoptosis of multiple myeloma cell line KM3 and its mechanisms.
Ge QF; Ouyang GF; Chen Y; Zhang Y; Mu QT; Lu Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Feb; 20(1):112-5. PubMed ID: 22391178
[TBL] [Abstract][Full Text] [Related]
25. [Establishment of BOR-Resistant U266 Cell Line and the Detection of Its Biological Activities].
Liu HL; Que WZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1722-1726. PubMed ID: 29262905
[TBL] [Abstract][Full Text] [Related]
26. The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.
Pattarozzi A; Carra E; Favoni RE; Würth R; Marubbi D; Filiberti RA; Mutti L; Florio T; Barbieri F; Daga A
Stem Cell Res Ther; 2017 May; 8(1):119. PubMed ID: 28545562
[TBL] [Abstract][Full Text] [Related]
27. Novel p97/VCP inhibitor induces endoplasmic reticulum stress and apoptosis in both bortezomib-sensitive and -resistant multiple myeloma cells.
Nishimura N; Radwan MO; Amano M; Endo S; Fujii E; Hayashi H; Ueno S; Ueno N; Tatetsu H; Hata H; Okamoto Y; Otsuka M; Mitsuya H; Matsuoka M; Okuno Y
Cancer Sci; 2019 Oct; 110(10):3275-3287. PubMed ID: 31368616
[TBL] [Abstract][Full Text] [Related]
28. [Arsenic trioxide enhances the effects of bortezomib, dexamethasone on multiple myeloma cell line KM3 in vitro.].
Ouyang GF; Lin MF
Zhonghua Xue Ye Xue Za Zhi; 2010 Apr; 31(4):240-3. PubMed ID: 20510040
[TBL] [Abstract][Full Text] [Related]
29. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
30. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
31. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998
[TBL] [Abstract][Full Text] [Related]
32. A Sialylated-Bortezomib Prodrug Strategy Based on a Highly Expressed Selectin Target for the Treatment of Leukemia or Solid Tumors.
Liu M; Tang X; Ding J; Liu M; Zhao B; Deng Y; Song Y
Pharm Res; 2019 Nov; 36(12):176. PubMed ID: 31686241
[TBL] [Abstract][Full Text] [Related]
33. Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells.
Manni S; Brancalion A; Mandato E; Tubi LQ; Colpo A; Pizzi M; Cappellesso R; Zaffino F; Di Maggio SA; Cabrelle A; Marino F; Zambello R; Trentin L; Adami F; Gurrieri C; Semenzato G; Piazza F
PLoS One; 2013; 8(9):e75280. PubMed ID: 24086494
[TBL] [Abstract][Full Text] [Related]
34. SGK Kinase Activity in Multiple Myeloma Cells Protects against ER Stress Apoptosis via a SEK-Dependent Mechanism.
Hoang B; Shi Y; Frost PJ; Mysore V; Bardeleben C; Lichtenstein A
Mol Cancer Res; 2016 Apr; 14(4):397-407. PubMed ID: 26869290
[TBL] [Abstract][Full Text] [Related]
35. Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma.
Kopecka J; Salaroglio IC; Righi L; Libener R; Orecchia S; Grosso F; Milosevic V; Ananthanarayanan P; Ricci L; Capelletto E; Pradotto M; Napoli F; Di Maio M; Novello S; Rubinstein M; Scagliotti GV; Riganti C
Lung Cancer; 2018 Jun; 120():34-45. PubMed ID: 29748013
[TBL] [Abstract][Full Text] [Related]
36. Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1-Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow.
Zhang C; Xu X; Trotter TN; Gowda PS; Lu Y; Suto MJ; Javed A; Murphy-Ullrich JE; Li J; Yang Y
Mol Cancer Ther; 2022 Feb; 21(2):347-358. PubMed ID: 34907087
[TBL] [Abstract][Full Text] [Related]
37. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
Dasmahapatra G; Patel H; Dent P; Fisher RI; Friedberg J; Grant S
Br J Haematol; 2013 Apr; 161(1):43-56. PubMed ID: 23360303
[TBL] [Abstract][Full Text] [Related]
38. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.
Chauhan D; Singh A; Brahmandam M; Podar K; Hideshima T; Richardson P; Munshi N; Palladino MA; Anderson KC
Blood; 2008 Feb; 111(3):1654-64. PubMed ID: 18006697
[TBL] [Abstract][Full Text] [Related]
39. Tetrahydrobiopterin induces proteasome inhibitor resistance and tumor progression in multiple myeloma.
Zhang H; Chen J; Zhang M; Zhao M; Zhang L; Liu B; Wang S
Med Oncol; 2022 Feb; 39(5):55. PubMed ID: 35150316
[TBL] [Abstract][Full Text] [Related]
40. SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma.
Salaroglio IC; Belisario DC; Bironzo P; Ananthanarayanan P; Ricci L; Digiovanni S; Fontana S; Napoli F; Sandri A; Facolmatà C; Libener R; Comunanza V; Grosso F; Gazzano E; Leo F; Taulli R; Bussolino F; Righi L; Papotti MG; Novello S; Scagliotti GV; Riganti C; Kopecka J
J Exp Clin Cancer Res; 2022 Feb; 41(1):75. PubMed ID: 35197103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
